SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its anticipated inclusion in the S&P 500, sparking excitement among investors who foresee potential institutional investment and a price surge akin to Palantir's after its inclusion. The community is actively discussing potential short squeezes, target prices, and the impact of the upcoming company summit and potential Federal Reserve rate cuts on the stock's performance. Some investors are cautioning against excessive optimism, citing previous instances where stocks experienced declines post-inclusion.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is trending as investors weigh its dividend yield against recent market performance, with some expressing frustration over underperformance compared to growth-focused ETFs. The community is actively debating whether to hold SCHD for long-term income or rotate into higher-growth opportunities, especially as some point to its heavy weighting in energy and healthcare sectors. Recent discussions also highlight anticipation for the next dividend announcement and how broader economic factors like interest rate cuts and potential tariffs might impact the ETF.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to its recent $100 million private placement and strategic move into Injective ($INJ.X) digital assets. The community is actively discussing potential short squeezes and the stock's volatile price action, while also debating the long-term prospects of PAPL given its financial situation. Some traders are wary of dilution, while others see significant upside potential due to the small float and high borrowing costs.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to increased attention on its low float and potential for a significant breakout, with some traders drawing comparisons to other low-float runners. Community members are closely watching key breakout levels, speculating about a potential meme run and a possible short squeeze. Some investors believe the company is undervalued considering recent property sales.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its Solana ($SOL.X) reward system for holders, emphasizing passive income and a strong community. The token's resilience and recent sponsorship with Kimbo Slice Jr. are also key talking points, with members highlighting the project's longevity and unique reward structure within the crypto space.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as chatter revolves around potential acquisition bids and analyst optimism for their drug candidate, AXPAXLI, despite recent market volatility. Community members speculate on buyout prices and partnerships, focusing on the upcoming SOL-1 data and its potential impact on valuation. Some traders are weighing OCUL against competitors in the wet AMD space, while others discuss the broader biotech sector trends.

Aventus

Aventus is trending, with community members highlighting a new partnership with The Truth Network. Bullish sentiment seems to be building with anticipation of a potential listing on a top 10 exchange. Some traders are pointing to the token's low market cap and limited supply as factors that could drive price appreciation.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as traders discuss its potential upside and key resistance levels, with some eyeing it as a safe haven amid market uncertainty. Community members are actively considering options strategies and anticipating a run toward specific price targets, while also monitoring news related to analyst ratings and potential tariff impacts. Broader discussions involve P&G's role as a defensive stock and its established history of dividend increases.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

Shares of ATYR are active amid ongoing discussions about upcoming data from a Phase 3 trial, with some speculating on a potential catalyst date while others assess the likelihood of success. Bullish sentiment is fueled by employee stock options and new hires, interpreted as confidence in positive results, although some traders are hedging their bets. The community is debating the company's financial moves and the potential impact of positive data on its long-term prospects.

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc

BEAM is trending as investors anticipate catalysts related to a September 14th date mentioned frequently across social media, though the specific event is unconfirmed, creating speculation and driving interest. Recent #BeamTherapeutics mentions include discussion around new data, comparisons to Wave Life Sciences ($WVE), and analysts highlighting Beam's base-editing advantages within the broader gene editing space, particularly for AATD.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's  What You Should Know

Oric Pharmaceuticals' stock hit its highest levels in three months on Thursday after the company unveiled promising preliminary results from its Phase 1b trial of ORIC-944, an AR inhibitor for metastatic castration-resistant prostate cancer (mCRPC).Shares of the pharma company soared 33.5% to close at $7.97 on Thursday.&nbsp;The company said that the trial showed potentially strong performance in both efficacy and safety, as 59% of patients reached a PSA50 response rate.&nbsp;This means that over half of the study participants saw an over 50% reduction in prostate-specific antigen (PSA) levels.Nearly all of these PSA responses were confirmed, and 24% of patients achieved PSA90 responses, indicating a 90% drop in PSA levels.The drug was tested with two established AR inhibitors — apalutamide (Erleada) and darolutamide (Nubeqa) — and PSA responses were consistent across all doses and both combinations.&nbsp;Most patients remained on therapy, with several approaching or surpassing one year of treatment duration.The safety profile was favorable because most adverse events were categorized as Grade 1 or 2.&nbsp;A single Grade 3 diarrhea event occurred, while no Grade 4 or 5 treatment-related events were linked to the medication.Meanwhile, ORIC also announced a $125 million private placement, which it said would extend its cash runway into the second half of 2027, covering the expected readout of its first global Phase 3 trial in 1H 2026.The initiation of ORIC's global registrational Phase 3 trial for ORIC-944 is planned for the first half of 2026.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 194% surge in 24-hour message volume.One user expressed optimism about the stock soon reaching $10 again.&nbsp;<stembedurl>https://stocktwits.com/OK78/message/616104324</stembedurl>However, another user questioned the private placement, suggesting it might be a setup for short sellers.They cited concerns over the company’s recent $125 million PIPE financing last year, which was initially expected to last through late 2026.&nbsp;“So, in the period of 12 months, they've diluted the stock with $250 million of new shares.”<stembedurl>https://stocktwits.com/Any_Day_Now/message/616156552</stembedurl>The stock has declined 3.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial

The company also announced a $125 million private placement to fund its upcoming Phase 3 trial for ORIC-944 in metastatic prostate cancer.

Equity

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration

OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration PR Newswire SAN FRANCISCO, Sept. 17...

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC
ORIC Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORIC News

ORIC ORIC Pharmaceuticals Inc